ClinicalTrials.gg
RecruitingNCT07077161SKIPPY 2Updated Aug 31, 2026

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

A Phase 2 interventional study of Cabozantinib in Renal Cell Carcinoma (RCC), sponsored by dr. Tom van der Hulle. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by dr. Tom van der Hulle · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.

Planned enrollment
27th of 43
34 · median 43
Started
2026
with 2 others
Phase 2
26 of 43
6 open now
Primary completion
2027-09
later than 14 of 22 live
Registered
40th of 43
by date
Lead sponsor
2 of 43
dr. Tom van der Hulle

Among the 43 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 27th largest by planned enrollment, is one of 3 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 14 of the 22 other live ones, and was the 40th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 43 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing cabozantinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The goal of this study is to determine if an alternative cabozantinib dosing regimens results in a similar drug exposure compared to the standard regimens in patients with metastatic renal cell carcinoma (mRCC). All dosages of cabozantinib (20 ,40, 60mg) have the same price, and cabozantinib is eliminated very slowly by the body. This means that using fewer tablets could potentially lead to cost savings, while remaining equally effective.

The main questions it aims to answer are:

  • Is the drug exposure from our experimental regimens similar to the standard dosing regimens?
  • Do the experimental regimens affect the number of side effect and the patients' quality of life?

Participants will:

  • Take cabozantinib according to either the experimental or standard dosage regimen for 4 weeks
  • After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires.
  • 1 and 3 days after this visit: visit the clinic to collect 1 blood sample.
  • The day after the hospital visit: switch to the other dosing regimen and according to that regimen for another 4 weeks.
  • After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires
  • 1 and 3 days after this visit: visit the clinic to collect 1 blood sample.
Read the detailed description

Standard regimens: 20 or 40mg once daily with standard breakfast

Experimental regimens:

  • Instead of 20mg once daily: 60mg for one day, followed by two skipping days (60-0-0). Also taken with standard breakfast.
  • Instead of 40mg once daily: 60mg for two days, followed by one skipping day (60-60-0). Also taken with standard breakfast.
03

Conditions studied

  • Renal Cell Carcinoma (RCC)

Keywords

  • Renal Cell Carcinoma
  • RCC
  • Cabozantinib
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide ;
  • Aged 18 years or older;
  • confirmed advanced renal cell carcinoma;
  • At least 4 weeks on a stable dosage of cabozantinib of 40 mg or 20 mg once daily as single-agent treatment or in combination with nivolumab;
  • Acceptable tolerability and the need for dose reductions or treatment interruptions has been estimated as low;
  • (ECOG) performance status of 0-2;
  • Estimated of ≥6 months;
  • No response evaluation planned during the study period.

Exclusion criteria

Exclusion Criteria:

  • Inability to follow the recommended standard breakfast;
  • Gastrointestinal abnormalities influencing the absorption of cabozantinib, including active inflammatory bowel disease, malabsorption syndrome, and prior major surgery of the stomach, pancreas, liver or small bowel.
  • Use of moderate or strong inhibitor of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including ketoconazole, grapefruit juice, clarithromycin, erythromycin, itraconazole and ritonavir.
  • Use of moderate or strong inducer of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including rifampicin, phenytoin, carbamazepine, phenobarbital and herbal preparations containing St. John's Wort.
  • Use of inhibitor of multidrug resistance-associated protein 2 within 1 month of start of treatment with cabozantinib, including cyclosporine, delavirdine, efavirenz, emtricitabine, benzbromarone and probenecid.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Active comparator
    Standard regimen

    taking 20mg or 40mg cabozantinib once daily with standard breakfast.

    Drug: Cabozantinib

Interventions

  • For patients using 40mg the experimental regimen consists of 60mg once daily for 2 days followed by 1 skipping day (60-60-0 mg). For patients using 20mg the experimental regimen consists of 60mg once daily for 1 day followed by 2 skipping days (60-0-0 mg). In both cases cabozantinib is also taken with standard breakfast.

06

What researchers measure

Primary outcomes

  1. Comparison of the AUC0-72h of the experimental and the standard regimen.

    AUC is calculated by modeliing a PK curve from plasma concentrations. AUCs are compared between the standard and experimental regimen.

    Time frame: From enrollment to the end of the study at approximately 2 months

  2. Comparison of blood trough concentration (Ctrough)

    Comparison of Ctrough, which is the plasma concentration of cabozantinib before ingestion of a dose cabozantinib, between the standard and experimental regimen.

    Time frame: From enrollment to the end of the study at approximately 2 months

Secondary outcomes

  1. Health-economic cost-consequences

    Calculating the cost-savings of the alternative dosing regimens

    Time frame: From enrollment to the end of the study at approximately 2 months

  2. Patients preference

    Patients preference of one of the dosing regimens.

    Time frame: From enrollment to the end of the study at 2 months

  3. Quality of life score

    Fill in a questionnaires (EQ-5D-5L) about the quality of life. Which looks into two things: 1. Five dimensions of health: mobility, self-care, daily activities, pain/disconfomrt and anxiety/some feelings. It uses a five point scale with 1 equally to no problem and 5 equally to extreme problems. It results in a score with 0 equally to dead and 1 equally to perfect health. 2. Subjective assessment of one's own health on a scale from 0 to 100. Where 0 equals worst imaginable health and 100 equals best imaginable health.

    Time frame: From enrollment to the end of the study at approximately 2 months

  4. Quality of life score

    Fill in a questionnaire (FKSI-19) with questions reflecting quality of life in patients with RCC. A question is answered using a 5-point scale where zero equals not at all and 4 equals very much. The higher the score the better the quality of life.

    Time frame: From enrollment to the end of the study at approximately 2 months

  5. Side effects: nausea and/or diarrhea

    Total number of patients experiencing nausea and/or diarrhea

    Time frame: From enrollment to the end of the study at approximately 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tan Z, Voller S, Yin A, Rieborn A, Gelderblom AJ, van der Hulle T, Knibbe CAJ, Moes DJAR. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens. Clin Pharmacokinet. 2024 Jun;63(6):857-869. doi: 10.1007/s40262-024-01379-y. Epub 2024 Jun 14. PubMed 38874883 ↗

Individual participant data

Plan to share: Undecided — To be determined in detail

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 19 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 22, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07077161
Lead sponsor
dr. Tom van der Hulle
Responsible party
dr. Tom van der Hulle (Principal Investigator, Leiden University Medical Center) — Sponsor-investigator
First posted
Jul 22, 2025
Start date
Jan 26, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Tom van der Hulle, MD PhD
Contact
t.van_der_hulle@lumc.nl
0031715263464
Nikki Kerssemakers, MSc
Contact
n.kerssemakers@lumc.nl
0031683139525
Tom van der Hulle, MD PhD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion